TaiMed Biologics Inc (中裕新藥) yesterday downplayed concerns about the company’s choice of distribution partner for its new HIV/AIDS drug TMB355, citing a robust business plan and advantages in tax management.
The company last month announced that it had inked an exclusive 12-year contract with Montreal-based Theratechnologies Inc to market its new drug in the US and Canada.
Analysts were downbeat on the partnership, casting doubts on the Canadian company’s ability to market the new drug compared with large companies.
“While Theratechnologies might not be a big name, marketing our product would be the company’s top priority,” TaiMed chief financial officer James Chen (陳怡成) said at an investors’ conference in Taipei.
Chen said larger companies might not be as motivated in marketing TMB355, as they tend to have many products in the mix, including their own new drug development initiatives.
He said that TMB355 would benefit from Theratechnologies’ history of working with HIV specialists across North America as a distributor of EGRIFTA — a treatment to reduce excess abdominal fat in HIV patients with lipodystrophy.
Chen added that the payment terms and timetable offered by Theratechnologies would yield more tax gains based on International Financial Reporting Standards 15 (IFRS), in addition to benefits from an agreement signed between Taiwan and Canada.
As for concerns over lower-than-expected payment terms for TMB355, Chen said that TaiMed retains a high level of control in how the new drug would be marketed in the future.
“You will see some of our peers booking cash income immediately, but their partners have effectively taken control of the drugs through licensing deals,” he said.
By contrast, once TMB355 gains approval from the US Food and Drug Administration (FDA), the company will seek other distribution partners for larger markets such as China, Chen said.
“Drug resistance is among the most challenging aspects of developing treatments for HIV/AIDS, and the situation is made worse when patients do not follow the regimen and administer the required injections daily,” he added.
TMB355 requires only a single injection daily, and its only competitor on the market is Fuzeon, which requires multiple daily injections, with 98 percent of patients using the drug reporting adverse side effects on their injection sites, Chen said.
Meanwhile, an intravenous injection of TMB355 has entered third-phase clinical trials, while an intramuscular and intradermal injection variant of the drug is undergoing first and second-phase trials.
The drug is expected to be approved by the US FDA in the first quarter of next year, he added.
The global market for HIV/AIDS treatments is expected to grow 7 percent this year to NT$500 billion, the company said, adding that more than 35 million people are infected with HIV worldwide, and less than 30 percent receive treatment.
Last year, the company reported an operating loss of NT$471 million, or losses of NT$2.16 per share.
SEMICONDUCTORS: The German laser and plasma generator company will expand its local services as its specialized offerings support Taiwan’s semiconductor industries Trumpf SE + Co KG, a global leader in supplying laser technology and plasma generators used in chip production, is expanding its investments in Taiwan in an effort to deeply integrate into the global semiconductor supply chain in the pursuit of growth. The company, headquartered in Ditzingen, Germany, has invested significantly in a newly inaugurated regional technical center for plasma generators in Taoyuan, its latest expansion in Taiwan after being engaged in various industries for more than 25 years. The center, the first of its kind Trumpf built outside Germany, aims to serve customers from Taiwan, Japan, Southeast Asia and South Korea,
Gasoline and diesel prices at domestic fuel stations are to fall NT$0.2 per liter this week, down for a second consecutive week, CPC Corp, Taiwan (台灣中油) and Formosa Petrochemical Corp (台塑石化) announced yesterday. Effective today, gasoline prices at CPC and Formosa stations are to drop to NT$26.4, NT$27.9 and NT$29.9 per liter for 92, 95 and 98-octane unleaded gasoline respectively, the companies said in separate statements. The price of premium diesel is to fall to NT$24.8 per liter at CPC stations and NT$24.6 at Formosa pumps, they said. The price adjustments came even as international crude oil prices rose last week, as traders
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which supplies advanced chips to Nvidia Corp and Apple Inc, yesterday reported NT$1.046 trillion (US$33.1 billion) in revenue for last quarter, driven by constantly strong demand for artificial intelligence (AI) chips, falling in the upper end of its forecast. Based on TSMC’s financial guidance, revenue would expand about 22 percent sequentially to the range from US$32.2 billion to US$33.4 billion during the final quarter of 2024, it told investors in October last year. Last year in total, revenue jumped 31.61 percent to NT$3.81 trillion, compared with NT$2.89 trillion generated in the year before, according to
SIZE MATTERS: TSMC started phasing out 8-inch wafer production last year, while Samsung is more aggressively retiring 8-inch capacity, TrendForce said Chipmakers are expected to raise prices of 8-inch wafers by up to 20 percent this year on concern over supply constraints as major contract chipmakers Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and Samsung Electronics Co gradually retire less advanced wafer capacity, TrendForce Corp (集邦科技) said yesterday. It is the first significant across-the-board price hike since a global semiconductor correction in 2023, the Taipei-based market researcher said in a report. Global 8-inch wafer capacity slid 0.3 percent year-on-year last year, although 8-inch wafer prices still hovered at relatively stable levels throughout the year, TrendForce said. The downward trend is expected to continue this year,
RSS